deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01885897

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions Acute Lymphoblastic Leukemia (ALL) Acute Myelogenous Leukemia (AML) Chronic Lymphocytic Leukemia (CLL) Chronic Myelogenous Leukemia (CML) Lymphoma Myelodysplastic Syndromes (MDS) Myeloma
Interventions ALT-803
Updated 16 times since 2017 Last updated: Jul 28, 2020 Started: Nov 11, 2013 Primary completion: Jul 31, 2019 Completion: Jul 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Acute Lymphoblastic Leukemia (ALL) and Acute Myelogenous Leukemia (AML), this trial is completed. The trial is conducted by Masonic Cancer Center, University of Minnesota and has accumulated 16 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Nov 2017 · 9 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Sep 2019 · 11 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

  2. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  3. May 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Dec 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Sep 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Oct 2018 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Nov 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Feb 2017 — Nov 2017 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Masonic Cancer Center, University of Minnesota
Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations